Pharmaceutical Technology

APRIL 22, 2024

AFNT-211 is under clinical development by Affini-T Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

52

52

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Pharmaceutical 52

Pharmaceutical 52

European Pharmaceutical Review

NOVEMBER 24, 2023

Amgen’s new immunotherapeutic agent Tarlatamab has been shown in a Phase II trial to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer patients. The international DeLLphi-301study was investigated as a new anti-cancer treatment option for patients previously considered to be beyond treatment.

Side effects 108

Side effects Patients Medicine Leads 108

Pharmaceutical Technology

APRIL 9, 2024

Prothea plans to use the funds to start clinical trial for cancer imaging, biopsy and laser ablation treatment in lung cancer patients.

Patients 52

Patients 52

Pharmaceutical Technology

APRIL 19, 2024

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

52

52

MedCity News

MARCH 20, 2023

BioNTech is expanding its cancer immunotherapy scope by partnering with OncoC4 on clinical testing of its lead drug. The antibody was designed to offer a safety edge over other CTLA-4-blocking drugs it’s on track for a Phase 3 test in non-small cell lung cancer.

Safety 90

Safety Leads Biopharma Pharma 90

Pharmaceutical Technology

APRIL 19, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer.

52

52

European Pharmaceutical Review

OCTOBER 12, 2023

Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. As the current landscape for lung cancer therapeutics stands, 39 small molecules have been commercialised.

Marketing 84

Marketing Sales Medicine FDA 84

European Pharmaceutical Review

DECEMBER 22, 2023

French pharmaceutical giant Sanofi announced that it is ending the development programme evaluating tusamitamab ravtansine as a monotherapy for certain patients with metastatic non-squamous, non-small cell lung cancer (NSCLC). It may be overexpressed in many different cancer types.

Pharmaceutical 104

Pharmaceutical Patients Healthcare Healthcare 104

MedCity News

APRIL 20, 2023

Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024.

Leads 115

Leads Biopharma Pharma 115

European Pharmaceutical Review

SEPTEMBER 29, 2023

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

Pharmaceutical 104

Pharmaceutical Safety Patients 104

European Pharmaceutical Review

SEPTEMBER 12, 2023

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. The findings also demonstrated a clinically meaningful benefit in median overall survival of 3.6 percent versus 27.5

Safety 98

Safety Patients Pharmaceutical 98

Medgadget

NOVEMBER 1, 2023

Researchers at the Wyss Institute at Harvard University have developed a microfluidic chip that can recreate some of the features of radiation-induced lung injury. The lungs are very sensitive to radiation, and this can limit the application of radiotherapy to treat cancer.

Ethics 106

Ethics Patients 106

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

APRIL 19, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Small Cell Lung Cancer.

Pharmaceutical 40

Pharmaceutical 40

European Pharmaceutical Review

AUGUST 29, 2023

The Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised the first subcutaneous formulation of an anti-PD-(L)1 cancer immunotherapy to be made available to patients in Great Britain. Tecentriq SC will be available on the NHS in Great Britain for certain types of lung, bladder, breast, and liver cancer.

Food and Drug Administration 86

Food and Drug Administration Safety Medicine Food 86

European Pharmaceutical Review

NOVEMBER 17, 2022

Final draft guidance published by the National Institute for Health and Care Excellence (NICE), recommends Mobocertinib (Exkivity), a new therapy that helps slow cancer growth in adults with epidermal growth factor receptor ( EGFR ) exon 20+ non-small-cell lung cancer (NSCLC), who have already received platinum-based chemotherapy.

Medicine 95

Medicine Patients Pharmaceutical 95

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

APRIL 19, 2024

GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer.

40

40

Pharmaceutical Technology

APRIL 19, 2024

JS-006 is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Non-Small Cell Lung Cancer.

40

40

Pharmaceutical Technology

APRIL 19, 2024

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Non-Small Cell Lung Cancer.

40

40

European Pharmaceutical Review

OCTOBER 9, 2023

The medicine is approved in the US for advanced KRAS G12C -mutated non-small cell lung cancer (NSCLC) in patients who have received at least one prior systemic treatment. The treatment has shown encouraging early efficacy data in NSCLC, bile duct cancer (cholangiocarcinoma) and melanoma.

Medicine 94

Medicine Patients Medical Pharmaceutical 94

European Pharmaceutical Review

OCTOBER 26, 2023

In August 2023, Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData shared that HER2-positive breast cancer “seems to be a major focus” in ADC drug development. Clinically meaningful PFS benefit was seen in patients with non-squamous tumours. Can you summarise the key new data from the TROPION-programme?

Patients 96

Patients Pharmaceutical Safety Marketing 96

pharmaphorum

JANUARY 17, 2023

and a clinical group in the UK to test an artificial intelligence-powered technology to help radiologists detecting lung cancer in chest X-rays. Greater Manchester has been selected as the site for the trial, as rates of lung cancer there are among the highest in the UK, said the partners. ” AZ and Qure.ai

Patients 90

Patients Government Pharma Training 90

Pharmaceutical Technology

APRIL 19, 2024

DF-4101 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer.

40

40

European Pharmaceutical Review

NOVEMBER 15, 2023

Roche’s monoclonal antibody cancer immunotherapy was recommended for all indications in which Tecentriq intravenous (IV) has been previously approved, including certain lung, liver, bladder and breast cancer types. Roche highlighted that Tecentriq SC can be injected in approximately seven minutes. months from the study.

Medicine 105

Medicine Safety Medical Patients 105

MedCity News

JANUARY 30, 2024

Even just a year ago, we couldn’t fathom a cure for cancer. Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans. AI algorithms can analyze medical images and identify any abnormalities that may indicate cancer. Now, we can.

Side effects 126

Side effects Ethics Medical Patients 126

European Pharmaceutical Review

NOVEMBER 6, 2023

A new medicine to treat adults with non-small cell lung cancer (NSCLC) with a rare mutation called KRAS G12C has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Mirati Therapeutics also shared in a press release that adagrasib has shown clinically to penetrate the central nervous system.

Medicine 90

Medicine Consulting Patients Medical 90

European Pharmaceutical Review

MAY 4, 2023

Data announced at the European Lung Cancer Congress (ELCC) earlier this month revealed the long-term efficacy and safety of RYBREVANT ® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). What are the current trends in antibody therapeutics?

Food and Drug Administration 93

Food and Drug Administration Safety Medicine Patients 93

PharmExec

MARCH 22, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

World of DTC Marketing

JANUARY 4, 2022

after they were diagnosed with metastatic colon cancer. According to the study “financial hardship or “financial toxicity” is an increasingly recognized consequence of cancer treatment that results from high out-of-pocket medical costs (e.g., National costs for cancer care were estimated to be $190.2

Insurance 273

Insurance Transportation Medical Prescription 273

European Pharmaceutical Review

JANUARY 16, 2024

The European Commission (EC) has approved the EU’s first PD-(L)1 cancer immunotherapy for subcutaneous injection. The company also highlighted that the intravenous (IV) infusion of Tecentriq was the first cancer immunotherapy approved for certain early-stage (adjuvant) NSCLCs, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC).

Safety 95

Safety Medical Patients Marketing 95

European Pharmaceutical Review

FEBRUARY 15, 2023

Final analyses of a Phase II trial for resectable non-small cell lung cancer (NSCLC) has concluded that 60 percent of patients treated with neoadjuvant nivolumab remained recurrence-free five years after surgery. Of the nine patients who had a major pathological response, eight were alive and cancer-free five years after treatment.

Food and Drug Administration 89

Food and Drug Administration Patients Food Networking 89

PharmExec

FEBRUARY 7, 2024

Results from the Phase III CheckMate -77T trial show that Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo produced statistically significant and clinically meaningful improvements in event-free survival in patients with resectable stage IIA to IIIB non-small cell lung cancer.

Patients 52

Patients 52

Pharmaceutical Technology

AUGUST 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults. According to the interim efficacy data from a pre-specified patient cohort, a 5.4

Food and Drug Administration 105

Food and Drug Administration FDA Safety Engineering 105

Pharmacy Times

DECEMBER 1, 2022

Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.

49

49

World of DTC Marketing

OCTOBER 6, 2020

WHAT’S THIS ABOUT THEN : Researchers are rushing to launch clinical trials of experimental vaccines against the coronavirus, and treatments for COVID-19. We are now seeing impacts on clinical-trial continuity in all the regions where we conduct clinical studies.”.

Patients 180

Patients Physicians Networking Pharmaceutical 180